<ul><li>Aurobindo Pharma exhibited slightly better-than-expected sales/Ebitda (2%/3% beat) for the quarter.</li><li>Aurobindo Pharma delivered the highest-ever quarterly Ebitda in Q4 FY25, led by a higher offtake in the US generics segment and steady traction in the EU segment.</li><li>Motilal Oswal reiterates Buy for Aurobindo Pharma's stock due to its attractive valuation of 16x FY26E EPS of Rs 73/14x FY27E EPS of Rs 83.5.</li></ul>

Aurobindo Pharma Q4 Review: Well-Placed To Capture Market Opportunities, Says Motilal Oswal, Maintaining Buy

Discover more